An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers

Trial Profile

An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Necitumumab (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Sep 2016 Results of pooled analysis (N=807) of (I4X-IE-JFCA,JFCB,JFCC, JFCI,JFCJ) published in the Clinical Pharmacokinetics (2016).
    • 15 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 16 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top